



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

16991.017

APPLICATION NO.

10/785,109

APPLICANTS

Masaaki GOTO *et al.*

FILING DATE

February 25, 2004

GROUP

1646

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION |
|---------------------|-----|--------------------|---------|---------|-------|---------------|-----------------------------|
| mbp | AAI | 0 784 093 A1 / | 07/1997 | EPO | | | Yes No |
| ↑ | ABI | 0 974 671 A1 / | 01/2000 | EPO | | | Yes No |
| | ACI | 1 127 578 A1 / | 08/2001 | EPO | | | Yes No |
| | ADI | 1 270 015 A2 / | 01/2003 | EPO | | | Yes No |
| | AEI | 1 270 015 A3 / | 02/2004 | EPO | | | Yes No |
| | AFI | 62-201825 / | 09/1987 | Japan | | | X Yes (abstract only) No |
| | AGI | 98/46211 A1 / | 10/1998 | PCT | | | Yes No |
| | AHI | 98/46644 A1 / | 10/1998 | PCT | | | X Yes (abstract only) No |
| | AII | 99/15691 A1 / | 04/1999 | PCT | | | X Yes (abstract only) No |
| | AJI | 01/44472 A1 / | 06/2001 | PCT | | | Yes No |
| ↓ | AKI | 03/002713 A2 / | 01/2003 | PCT | | | Yes No |
| mbp | ALI | 03/074084 A1 / | 09/2003 | PCT | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|-----|-------|--|
| mbp | AMI / | Jean-Jacques Body, "Current and Future Directions in Medical Therapy: Hypercalcemia," <i>CANCER Supplement</i> , 88(12):3054-3058 (2000) |
| mbp | ANI / | <i>Chemical Abstracts</i> , Vol. 123, No. 18, Abstract No. 237583p (1995) |
| mbp | AOI / | Chowdhury <i>et al.</i> , "Effects of Heparin on Osteoclast Activity," <i>Journal of Bone and Mineral Research</i> , 7(7):771-777 (1992) |

EXAMINER

MICHAEL PIAN

DATE CONSIDERED

10/16/06 3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | |
|--|-------|--|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | 16991.017 | 10/785,109 |
| | | APPLICANTS | |
| | | Masaaki GOTO <i>et al.</i> | |
| | | FILING DATE | GROUP |
| | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | |
| WPP | AA2 / | Cochran and Abernathy, "Modulation of Bone Resorption by Glycosaminoglycans: Effects of Parathyroid Hormone and Interleukin-1," <i>Bone</i> , 9(5):331-335 (1988) | |
| ↑ | AB2 / | Fautrel and Guillemain, "Cost of illness studies in rheumatic diseases," <i>Current Opinion in Rheumatology</i> , 14:121-126 (2002) | |
| | AC2 / | Green <i>et al.</i> , "Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short-Term Rat Models," <i>Pharmacology & Toxicology</i> , 80:225-230 (1997) | |
| | AD2 / | Iqbal and Sobhan, "Osteoporosis: A Review," <i>Missouri Medicine</i> , 99(1):19-24 (2002) | |
| | AE2 / | Porcel <i>et al.</i> , "Anaphylaxis to calcitonin," <i>Allergologia et immunopathologia</i> , 28(4):243-245 (2000) | |
| | AF2 / | Romas <i>et al.</i> , "Involvement of Receptor Activator of NFκB Ligand and Tumor Necrosis Factor-α in Bone Destruction in Rheumatoid Arthritis," <i>Bone</i> , 30(2):340-346 (2002) | |
| | AG2 / | Tomoyasu <i>et al.</i> , "Characterization of Monomeric and Homodimeric Forms of Osteoclastogenesis Inhibitory Factor," <i>Biochemical and Biophysical Research Communications</i> , 245(2):382-387 (1998) | |
| ↓ | AH2 / | White and Schilling, "Postmenopausal Hormone Replacement: Historical Perspectives and Current Concerns," <i>Clinical Excellence for Nurse Practitioners</i> , 4(5):277-285 (2000) | |
| WPP | AI2 / | Yamamoto <i>et al.</i> , "Hypocalcemic Effect of Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in the Thyroparathyroidectomized Rat," <i>Endocrinology</i> , 139(9):4012-4015 (1998) | |
| | AJ2 | | |
| | AK2 | | |
| EXAMINER | | | DATE CONSIDERED |
| MICHAEL PHIL | | | 3-16-06 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | |

| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | | ATTY. DOCKET NO. | | APPLICATION NO. | |
|--|-----|--------------------|---------|----------------------------|-----------------|-----------------|-------------|
| | | | | 16991.017 | | 10/785,109 | |
| | | | | APPLICANTS | | | |
| | | | | Masaaki GOTO <i>et al.</i> | | | |
| FILING DATE | | | | GROUP | | | |
| February 25, 2004 | | | | 1646 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
| MDP | AA3 | 4,179,337 | 12/1979 | Davis <i>et al.</i> | | | |
| ↑ | AB3 | 4,710,473 | 12/1987 | Morris | | | |
| | AC3 | 4,959,314 | 09/1990 | Mark <i>et al.</i> | | | |
| | AD3 | 5,118,667 | 06/1992 | Adams <i>et al.</i> | | | |
| | AE3 | 5,366,859 | 11/1994 | Miyoshi <i>et al.</i> | | | |
| | AF3 | 5,374,529 | 12/1994 | Caterson <i>et al.</i> | | | |
| | AG3 | 5,393,739 | 02/1995 | Bentz <i>et al.</i> | | | |
| | AH3 | 5,427,954 | 06/1995 | Sandy <i>et al.</i> | | | |
| | AI3 | 5,447,851 | 09/1995 | Beutler <i>et al.</i> | | | |
| | AJ3 | 5,457,035 | 10/1995 | Baum <i>et al.</i> | | | |
| | AK3 | 5,545,722 | 08/1996 | Naka | | | |
| | AL3 | 5,578,569 | 11/1996 | Tam | | | |
| | AM3 | 5,585,479 | 12/1996 | Hoke <i>et al.</i> | | | |
| | AN3 | 5,599,708 | 02/1997 | Mundy <i>et al.</i> | | | |
| | AO3 | 5,658,756 | 08/1997 | Rodan <i>et al.</i> | | | |
| | AP3 | 5,736,506 | 04/1998 | Naka | | | |
| | AQ3 | 5,830,850 | 11/1998 | Gelb <i>et al.</i> | | | |
| | AR3 | 5,843,678 | 12/1998 | Boyle | | | |
| | AS3 | 5,843,901 | 12/1998 | Roeske | | | |
| | AT3 | 5,985,832 | 11/1999 | Roodman <i>et al.</i> | | | |
| ↓ | AU3 | 6,015,938 | 01/2000 | Boyle <i>et al.</i> | | | |
| MDP | AV3 | 6,017,729 | 01/2000 | Anderson <i>et al.</i> | | | |
| EXAMINER | | | | | DATE CONSIDERED | | |
| MICHAEL PHU | | | | | 3-16-06 | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | | | | |

| | | | | | | | |
|---|--|--|--|----------------------------|--|-----------------|--|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTY. DOCKET NO. | | APPLICATION NO. | |
| | | | | 16991.017 | | 10/785,109 | |
| | | | | APPLICANTS | | | |
| | | | | Masaaki GOTO <i>et al.</i> | | | |
| FILING DATE | | | | GROUP | | | |
| February 25, 2004 | | | | 1646 | | | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----|--------------------|---------|-------------------------|-------|---------------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
| MDP ↑ | AA4 | 6,046,033 | 04/2000 | Goto <i>et al.</i> | | | |
| | AB4 | 6,087,555 | 07/2000 | Dunstan <i>et al.</i> | | | |
| | AC4 | 6,242,213 B1 | 06/2001 | Anderson | | | |
| | AD4 | 6,242,586 B1 | 06/2001 | Gorman <i>et al.</i> | | | |
| | AE4 | 6,271,349 B1 | 07/2001 | Dougall <i>et al.</i> | | | |
| | AF4 | 6,284,485 B1 | 09/2001 | Boyle <i>et al.</i> | | | |
| | AG4 | 6,284,728 B1 | 09/2001 | Boyle <i>et al.</i> | | | |
| | AH4 | 6,284,740 B1 | 09/2001 | Boyle <i>et al.</i> | | | |
| | AI4 | 6,288,032 B1 | 09/2001 | Boyle <i>et al.</i> | | | |
| | AJ4 | 6,297,022 B1 | 10/2001 | McDonnell <i>et al.</i> | | | |
| | AK4 | 6,316,408 B1 | 11/2001 | Boyle | | | |
| | AL4 | 6,369,027 B1 | 04/2002 | Boyle <i>et al.</i> | | | |
| | AM4 | 6,419,929 B1 | 07/2002 | Anderson | | | |
| | AN4 | 6,479,635 B1 | 11/2002 | Anderson <i>et al.</i> | | | |
| | AO4 | 6,525,180 B1 | 02/2003 | Gorman <i>et al.</i> | | | |
| | AP4 | 6,528,482 B1 | 03/2003 | Anderson <i>et al.</i> | | | |
| | AQ4 | 6,537,763 B1 | 03/2003 | Dougall <i>et al.</i> | | | |
| | AR4 | 6,562,948 B2 | 05/2003 | Anderson | | | |
| | AS4 | 6,613,544 B1 | 09/2003 | Boyle <i>et al.</i> | | | |
| | AT4 | 6,649,164 B2 | 11/2003 | Maraskovsky | | | |
| ↓ MDP | AU4 | 6,693,175 B2 | 02/2004 | Yano <i>et al.</i> | | | |
| | AV4 | 6,740,522 B2 | 05/2004 | Anderson | | | |

| | |
|---|---|
| EXAMINER <div style="text-align: center; font-family: cursive; font-size: 1.2em;">MICHAEL PARN</div> | DATE CONSIDERED <div style="text-align: center; font-family: cursive; font-size: 1.2em;">3-16-06</div> |
|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|---|----------------------------|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. | APPLICATION NO. |
| | 16991.017 | 10/785,109 |
| | APPLICANTS | |
| | Masaaki GOTO <i>et al.</i> | |
| | FILING DATE | GROUP |
| | February 25, 2004 | 1646 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|---------------------|-----|--------------------|---------|-------------------------|-------|---------------|-------------|
| MDP | AA5 | 2002/0081720 A1 | 06/2002 | Dougall <i>et al.</i> | | | |
| ↑ | AB5 | 2002/0086826 A1 | 07/2002 | Anderson <i>et al.</i> | | | |
| | AC5 | 2002/0086827 A1 | 07/2002 | Anderson <i>et al.</i> | | | |
| | AD5 | 2002/0127637 A1 | 09/2002 | Jian <i>et al.</i> | | | |
| | AE5 | 2002/0150989 A1 | 10/2002 | Greene <i>et al.</i> | | | |
| | AF5 | 2002/0169117 A1 | 11/2002 | Maraskovsky | | | |
| | AG5 | 2003/0045456 A1 | 03/2003 | Yamamoto <i>et al.</i> | | | |
| | AH5 | 2003/0100069 A1 | 05/2003 | Jian <i>et al.</i> | | | |
| | AI5 | 2003/0100488 A1 | 05/2003 | Boyle | | | |
| | AJ5 | 2003/0103978 A1 | 06/2003 | Deshpande <i>et al.</i> | | | |
| | AK5 | 2003/0104485 A1 | 06/2004 | Boyle | | | |
| | AL5 | 2003/0139325 A1 | 07/2003 | Yamamoto <i>et al.</i> | | | |
| | AM5 | 2003/0144480 A1 | 07/2003 | Gorman <i>et al.</i> | | | |
| | AN5 | 2003/0166097 A1 | 09/2003 | Greene <i>et al.</i> | | | |
| | AO5 | 2003/0175840 A1 | 09/2003 | Anderson <i>et al.</i> | | | |
| | AP5 | 2003/0176647 A1 | 09/2003 | Yamaguchi <i>et al.</i> | | | |
| | AQ5 | 2003/0181418 A1 | 09/2003 | Kumakura <i>et al.</i> | | | |
| | AR5 | 2003/0207827 A1 | 11/2003 | Boyle <i>et al.</i> | | | |
| | AS5 | 2003/0208045 A1 | 11/2003 | Yamaguchi <i>et al.</i> | | | |
| ↓ | AT5 | 2003/0216297 A1 | 11/2003 | Kumakura <i>et al.</i> | | | |
| MDP | AU5 | 2004/0033535 A1 | 02/2004 | Boyle <i>et al.</i> | | | |

EXAMINER

MICHAEL POK

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|--|--|--|----------------------------|--|-----------------|--|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | | ATTY. DOCKET NO. | | APPLICATION NO. | |
| | | | | 16991.017 | | 10/785,109 | |
| | | | | APPLICANTS | | | |
| | | | | Masaaki GOTO <i>et al.</i> | | | |
| FILING DATE | | | | GROUP | | | |
| February 25, 2004 | | | | 1646 | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-------------|--------------------|---------|-------------|-------|---------------|-----------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION |
| | AA6 | 0514130 A2 | 11/1992 | EPO | | | Yes No |
| | AB6 | 0514130 A3 | 11/1992 | EPO | | | Yes No |
| | AC6 | 0526905 A2 | 02/1993 | EPO | | | Yes No |
| | AD6 | 0526905 A3 | 02/1993 | EPO | | | Yes No |
| | AE6 | 0727211 A1 | 08/1996 | EPO | | | Yes No |
| | AF6 | 0874045 A1 | 10/1998 | EPO | | | Yes No |
| | AG6 | 0911342 A1 | 04/1999 | EPO | | | Yes No |
| | AH6 | 330400 | 05/1999 | New Zealand | | | Yes No |
| | AI6 | 86/00922 A1 | 02/1986 | PCT | | | Yes No |
| | AJ6 | 90/14363 A1 | 11/1990 | PCT | | | Yes No |
| | AK6 | 93/12227 A1 | 06/1993 | PCT | | | Yes No |
| | AL6 | 93/21946 A1 | 11/1993 | PCT | | | Yes No |
| | AM6 | 95/11308 A1 | 04/1995 | PCT | | | Yes No |
| | AN6 | 96/28546 A1 | 09/1996 | PCT | | | Yes No |
| | AO6 | 97/00317 A1 | 01/1997 | PCT | | | Yes No |
| | AP6 | 97/00318 A1 | 01/1997 | PCT | | | Yes No |
| | AQ6 | 97/23614 A1 | 07/1997 | PCT | | | Yes No |
| | AR6 | 98/07840 A1 | 02/1998 | PCT | | | Abstract X only Yes No |
| | AS6 | 98/25958 A2 | 06/1998 | PCT | | | Yes No |
| | AT6 | 98/28424 A2 | 07/1998 | PCT | | | Yes No |
| AU6 | 98/28426 A2 | 07/1998 | PCT | | | Yes No | |

| | |
|---------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| MICHAEL [Signature] | 3-16-06 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | | ATTY. DOCKET NO. | | APPLICATION NO. | | |
|--|-----|--------------------|---|---|-------|-----------------|-------------|-----------|
| | | | | 16991.017 | | 10/785,109 | | |
| | | | | APPLICANTS | | | | |
| | | | | Masaaki GOTO <i>et al.</i> | | | | |
| | | | | FILING DATE | | GROUP | | |
| | | | | February 25, 2004 | | 1646 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION | |
| MOP | AA7 | 98/46751 A1 | 10/1998 | PCT | | | Yes No | |
| ↑ | AB7 | 98/49305 A1 | 11/1998 | PCT | | | Yes No | |
| | AC7 | 99/19468 A1 | 04/1999 | PCT | | | Yes No | |
| | AD7 | 99/53942 A1 | 10/1999 | PCT | | | Yes No | |
| | AE7 | 99/58674 A2 | 11/1999 | PCT | | | Yes No | |
| | AF7 | 99/58674 A3 | 11/1999 | PCT | | | Yes No | |
| | AG7 | 01/03719 A2 | 01/2001 | PCT | | | Yes No | |
| | AH7 | 01/03719 A3 | 01/2001 | PCT | | | Yes No | |
| | AI7 | 01/17543 A2 | 03/2001 | PCT | | | Yes No | |
| | ↓ | AJ7 | 01/17543 A3 | 03/2001 | PCT | | | Yes No |
| | MPP | AK7 | 01/18203 A1 | 03/2001 | PCT | | | Yes No |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | | |
| MOP | AL | 7 | Adams <i>et al.</i> , "Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project", <i>Science</i> , 252:1651-1656 (1991) | | | | | |
| ↑ | AM | 7 | Anderson <i>et al.</i> , "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", <i>Nature</i> , 390:175-179 (1997) | | | | | |
| | AN | 7 | Banks <i>et al.</i> , "Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?", <i>European Journal of Clinical Investigation</i> , 24(12):813-817 (1994) | | | | | |
| | AO | 7 | Banner <i>et al.</i> , "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation", <i>Cell</i> , 73(3):431-445 (1993) | | | | | |
| | ↓ | AP | 7 | Bennett, C. F., "Antisense Research", <i>Science</i> , 271:434 (1996) | | | | |
| MPP | AQ | 7 | Beutler and Cerami, "Tumor Necrosis, Cachexia, Shock, and Inflammation: a Common Mediator", <i>Annual Review of Biochemistry</i> , 57:505-518 (1988) | | | | | |
| EXAMINER | | | | | | DATE CONSIDERED | | |
| MICHAEL MPP | | | | | | 3-16-06 | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | | | | | |

| | | | | |
|--|----|---|---|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| MDP ↑ | AA | 8 | Beutler and van Huffer, "Unraveling Function in the TNF Ligand and Receptor Families", <i>Science</i> , 264:667-668 (1994) | |
| | AB | 8 | Boyce <i>et al.</i> , "Effects of Interleukin-1 on Bone Turnover in Normal Mice", <i>Endocrinology</i> , 125(3):1142-1150 (1989) | |
| | AC | 8 | Bradley and Robertson, "Embryo-Derived Stem Cells: a Tool for Elucidating the Developmental Genetics of the Mouse", <i>Current Topics in Developmental Biology</i> , 20:357-371 (1986) | |
| | AD | 8 | Brinster <i>et al.</i> , "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs", <i>Proceedings of the National Academy of Sciences of USA</i> , 82:4438-4442 (1985) | |
| | AE | 8 | Bucay <i>et al.</i> , "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", <i>Genes and Development</i> , 12(9):1260-1268 (1998) | |
| | AF | 8 | Capon <i>et al.</i> , "Designing CD4 immunoadhesins for AIDS therapy", <i>Nature</i> , 337(6207):525-531 (1989) | |
| | AG | 8 | Cappecchi, M. R., "Altering the Genome by Homologous Recombination", <i>Science</i> , 244:1288-1292 (1989) | |
| | AH | 8 | Chambers <i>et al.</i> , "Generation of osteoclast-inductive and osteoclastogenic cell lines from the <i>H-2K^bIsA58</i> transgenic mouse", <i>Proceedings of the National Academy of Sciences of USA</i> , 90:5578-5582 (1993) | |
| | AI | 8 | Charreau <i>et al.</i> , "Transgenesis in rats: technical aspects and models", <i>Transgenic Research</i> , 5(4):223-234 (1996) | |
| | AJ | 8 | Chen <i>et al.</i> , "Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor- α to Its Two Receptors", <i>Journal of Biological Chemistry</i> , 270(6):2874-2878 (1995) | |
| ↓ | AK | 8 | Chenu <i>et al.</i> , "Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 85(15):5683-5687 (1988) | |
| | AL | 8 | Chomczynski and Sacchi, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", <i>Analytical Biochemistry</i> , 162(1):156-159 (1987) | |
| MDP | AM | 8 | Culver and Blaese, "Gene therapy for cancer", <i>Trends in Genetics</i> , 10(5):174-178 (1994) | |
| EXAMINER | | | DATE CONSIDERED | |
| MICHAEL PAM | | | 3-16-06 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |

| | | | | |
|---|--|--|----------------------------|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |

| | | | |
|-----|----|---|--|
| MOP | AA | 9 | Database EMBEST16, EMBL Database Accession No. AA170348 <i>no date</i> |
| ↑ | AB | 9 | Database GenEMBL, EMBL Accession No. AF019048 <i>no date</i> |
| | AC | 9 | Database EMROD, EMBL Database Accession No. M59378 <i>no date</i> |
| | AD | 9 | DeClerck <i>et al.</i> , "Inhibition of Autoproteolytic Activation of Interstitial Procollagenase by Recombinant Metalloproteinase Inhibitor MI/TIMP-2", <i>Journal of Biological Chemistry</i> , 266(6):3893-3899 (1991) |
| | AE | 9 | Demer, L. L., "A Skeleton in the Atherosclerosis Closet", <i>Circulation</i> , 92(8):2029-2032 (1995) |
| | AF | 9 | Ebi <i>et al.</i> , "Mechanism of Mast Cell Deficiency in Mutant Mice of <i>mi/mi</i> Genotype: An Analysis by Co-Culture of Mast Cells and Fibroblasts", <i>Blood</i> , 75(6):1247-1251 (1990) |
| | AG | 9 | Efrat, S., "Prospects for gene therapy of insulin-dependent diabetes mellitus", <i>Diabetologia</i> , 41(12):1401-1409 (1998) |
| | AH | 9 | Ellison <i>et al.</i> , "The nucleotide sequence of a human immunoglobulin C _{γ1} gene", <i>Nucleic Acids Research</i> , 10(13):4071-4079 (1982) |
| | AI | 9 | Engels and Uhlmann, "Gene Synthesis", <i>Angew. Chem. Int. Ed. Engl.</i> , 28:716-734 (1989) |
| | AJ | 9 | Fawthrop <i>et al.</i> , "The Effect of Transforming Growth Factor β on the Plasminogen Activator Activity of Normal Human Osteoblast-like Cells and a Human Osteosarcoma Cell Line MG-63", <i>Journal of Bone and Mineral Research</i> , 7(12):1363-1371 (1992) |
| | AK | 9 | Fenton <i>et al.</i> , "Long-Term Culture of Disaggregated Rat Osteoclasts: Inhibition of Bone Resorption and Reduction of Osteoclast-Like Cell Number by Calcitonin and PTHrP[107-139]", <i>Journal of Cellular Physiology</i> , 155:1-7 (1993) |
| | AL | 9 | Fisher <i>et al.</i> , "Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome", <i>Cell</i> , 81(6):935-946 (1995) |
| ↓ | AM | 9 | Galli-Taliadoros <i>et al.</i> , "Gene knock-out technology: a methodological overview for the interested novice", <i>Journal of Immunological Methods</i> , 181(1):1-15 (1995) |
| MOP | AN | 9 | George <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis", <i>Macromolecular Sequencing and Synthesis Selected Methods and Applications</i> , pp. 127-149 (1988) |

| | |
|-------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| MICHAEL PPH | 3-16-06 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | |
|--|----|----|---|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO et al. | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| MOP | AA | 11 | Kaji et al., "Insulin-Like Growth Factor-I Mediates Osteoclast-Like Cell Formation Stimulated by Parathyroid Hormone", <i>Journal of Cellular Physiology</i> , 172(1):55-62 (1997) | |
| ↑ | AB | 11 | Karaplis, A. C., "Gene Targeting", <i>Principles of Bone Biology</i> , pp. 1189-1201, Academic Press (1996) | |
| | AC | 11 | Kasano et al., "Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture", <i>Bone and Mineral</i> , 21(3):179-188 (1993) | |
| | AD | 11 | Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(21):8331-8335 (1990) | |
| | AE | 11 | Kraulis, P. J., " <i>MOLSCRIPT</i> : a program to produce both detailed and schematic plots of protein structures", <i>Journal of Applied Crystallography</i> , 24(5):946-950 (1991) | |
| | AF | 11 | Kukita et al., "Osteoinductive factor inhibits formation of human osteoclast-like cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 87:3023-3026 (1990) | |
| | AG | 11 | Lacey et al., "Interleukin 4, Interferon-γ, and Prostaglandin E Impact the Osteoclastic Cell-Forming Potential of Murine Bone Marrow Macrophages", <i>Endocrinology</i> , 136(6):2367-2376 (1995) | |
| | AH | 11 | Levine and Williams, "Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis", <i>Clinical Chemistry</i> , 43(4):669-674 (1997) | |
| | AI | 11 | Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific", <i>Proceedings of the National Academy of Sciences of USA</i> , 88:2830-2834 (1991) | |
| | AJ | 11 | Loetscher et al., "Tumor Necrosis Factor: Receptors and Inhibitors", <i>Cancer Cells</i> , 3(6):221-226 (1991) | |
| | AK | 11 | Lowe et al., "Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts" <i>Proceedings of the National Academy of Sciences of USA</i> , 90(10):4485-4489 (1993) | |
| ↓ | AL | 11 | Lüthy et al., "Improving the sensitivity of the sequence profile method", <i>Protein Science</i> , 3(1):139-146 (1994) | |
| MOP | AM | 11 | MacDonald et al., "Isolation of RNA Using Guanidinium Salts", <i>Methods in Enzymology</i> , 152:219-227 (1987) | |
| EXAMINER | | | DATE CONSIDERED | |
| Michael Roh | | | 3-16-06 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |

| | | | | |
|--|----|----|--|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| MOP | AA | 12 | Maitland and McDougal, "Biochemical Transformation of Mouse Cells by Fragments of Herpes Simplex Virus DNA", <i>Cell</i> , 11(1):233-241 (1977) | |
| ↑ | AB | 12 | Marks, Jr., and Lane, "Osteopetrosis, a New Recessive Skeletal Mutation on Chromosome 12 of the Mouse", <i>Journal of Heredity</i> , 67(1):11-18 (1976) | |
| | AC | 12 | Marshall, E., "Gene Therapy's Growing Pains", <i>Science</i> , 269:1050-1055 (1995) | |
| | AD | 12 | Martin <i>et al.</i> , "Interleukins in the Control of Osteoclast Differentiation", <i>Critical ReviewsTM in Eukaryotic Gene Expression</i> , 8(2):107-23 (1998) | |
| | AE | 12 | Matsudaira, P., "Sequence from Picomole Quantities of Proteins Electrophoretically Blotted onto Polyvinylidene Difluoride Membranes", <i>Journal of Biological Chemistry</i> , 262(21):10035-10038 (1987) | |
| | AF | 12 | Miller and Vile, "Targeted vectors for gene therapy", <i>FASEB Journal</i> , 9(2):190-199 (1995) | |
| | AG | 12 | Miller and Vile, "Gene Transfer and Antisense Nucleic Acid Techniques", <i>Parasitology Today</i> , 10(3):92-97 (1994) | |
| | AH | 12 | Milligan <i>et al.</i> , "Current Concepts in Antisense Drug Design", <i>Journal of Medicinal Chemistry</i> , 36(14):1923-1937 (1993) | |
| | AI | 12 | Mizuno <i>et al.</i> , "Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin", <i>Biochemical and Biophysical Research Communications</i> , 247(3):610-615 (1998) | |
| | AJ | 12 | Montgomery <i>et al.</i> , "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family", <i>Cell</i> , 87(3):427-436 (1996) | |
| | AK | 12 | Morony <i>et al.</i> , "A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1 β , TNF- α , PTH, PTHrP, and 1,25(OH) $_2$ D $_3$ ", <i>Journal of Bone and Mineral Research</i> , 14(9):1478-1485 (1999) | |
| ↓ | AL | 12 | Mundy <i>et al.</i> , "The Effects of Cytokines and Growth Factors on Osteoblastic Cells", <i>Bone</i> , 17(2 Suppl):71S-75S (1995) | |
| MOP | AM | 12 | Nagata and Golstein, "The Fas Death Factor", <i>Science</i> , 267:1449-1456 (1995) | |
| EXAMINER | | | DATE CONSIDERED | |
| MICHAEL PBL | | | 3-16-06 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |

| | | | | |
|--|----|----|---|-----------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| MPP | AA | 13 | Ogden and Adams, "Electrophoresis in Agarose and Acrylamide Gels", <i>Methods in Enzymology</i> , 152:61-87 (1987) | |
| ↑ | AB | 13 | Parhami and Demer, "Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids", <i>Current Opinion in Lipidology</i> , 8(5):312-314 (1997) | |
| | AC | 13 | Pearson, W. R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", <i>Methods in Enzymology</i> , 183:63-98 (1990) | |
| | AD | 13 | Perigaud <i>et al.</i> , "Nucleoside analogues as chemotherapeutic agents: a review", <i>Nucleosides & Nucleotides</i> , 11(2-4):903-945 (1992) | |
| | AE | 13 | Reddi, A. H., "Bone Morphogenesis and Modeling: Soluble Signals Sculpt Osteosomes in the Solid State", <i>Cell</i> , 89:159-161 (1997) | |
| | AF | 13 | Rieger <i>et al.</i> , <i>Glossary of Genetics and Cytogenetics</i> , p. 17, Springer-Verlag, Berlin Heidelberg, New York (1976) | |
| | AG | 13 | Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996) | |
| | AH | 13 | Roodman, G. D., "Role of Cytokines in the Regulation of Bone Resorption", <i>Calcified Tissue International</i> , 53(Suppl. 1):S94-S98 (1993) | |
| | AI | 13 | Rosati <i>et al.</i> , "Normal long bone growth and development in type X collagen-null mice", <i>Nature Genetics</i> , 8(2):129-135 (1994) | |
| | AJ | 13 | Schinke <i>et al.</i> , "Molecular determinants of arterial calcification", <i>Annals of Medicine</i> , 30(6):538-541 (1998) | |
| | AK | 13 | Shahinian <i>et al.</i> , "Differential T Cell Costimulatory Requirements in CD28-Deficient Mice", <i>Science</i> , 261:609-612 (1993) | |
| ↓ | AL | 13 | Siddhanti <i>et al.</i> , "Molecular to Pharmacologic Control of Osteoblast Proliferation and Differentiation", <i>Journal of Cellular Biochemistry</i> , 55(3):310-320 (1994) | |
| MPP | AM | 13 | Simonet <i>et al.</i> , "Long-term Impaired Neutrophil Migration in Mice Overexpressing Human Interleukin-8", <i>Journal of Clinical Investigation</i> , 94(3):1310-1319 (1994) | |
| EXAMINER | | | DATE CONSIDERED | |
| MICHAEL PM | | | 3-16-06 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |

| | | | | |
|--|----|--|--|-----------------|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| | AA | 14 | Simonet <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", <i>Cell</i> , 89:309-319 (1997) | |
| | AB | 14 | Smith <i>et al.</i> , "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death", <i>Cell</i> , 76:959-962 (1994) | |
| | AC | 14 | Soriano <i>et al.</i> , "Targeted Disruption of the c-src Proto-Oncogene Leads to Osteopetrosis in Mice", <i>Cell</i> , 64(4):693-702 (1991) | |
| | AD | 14 | Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?", <i>Science</i> , 261:1004-1012 (1993) | |
| | AE | 14 | Stull and Szoka, Jr., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Research</i> , 12(4):465-483 (1995) | |
| | AF | 14 | Suda <i>et al.</i> , "Modulation of Osteoclast Differentiation by Local Factors", <i>Bone</i> , 17(2 Suppl):87S-91S (1995) | |
| | AG | 14 | Suda <i>et al.</i> , "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family", <i>Cell</i> , 75(6):1169-1178 (1993) | |
| | AH | 14 | Takada <i>et al.</i> , "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", <i>Bone and Mineral</i> , 17:347-359 (1992) | |
| | AI | 14 | Tsuda <i>et al.</i> , "Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis", <i>Biochemical and Biophysical Research Communications</i> , 234(1):137-142 (1997) | |
| | AJ | 14 | Udagawa <i>et al.</i> , "The Bone Marrow-Derived Stromal Cell Lines MC3T3-G2/PA6 and ST2 Support Osteoclast-Like Cell Differentiation in Cocultures with Mouse Spleen Cells", <i>Endocrinology</i> , 125(3):1805-1813 (1989) | |
| | AK | 14 | Udagawa <i>et al.</i> , "Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(18):7260-7264 (1990) | |
| AL | 14 | Wagner, R. W., "Gene inhibition using antisense oligodeoxynucleotides", <i>Nature</i> , 372(6504):333-335 (1994) | | |
| AM | 14 | Wang, "Bone and haematopoietic defects in mice lacking c-fos", <i>Nature</i> , 360(6406):741-745 (1992) | | |
| EXAMINER | | | DATE CONSIDERED | |
| MICHAEL J. M. | | | 3-16-04 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |

| | | | | |
|--|----|----|---|---|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | | | ATTY. DOCKET NO. | APPLICATION NO. |
| | | | 16991.017 | 10/785,109 |
| | | | APPLICANTS | |
| | | | Masaaki GOTO <i>et al.</i> | |
| | | | FILING DATE | GROUP |
| | | | February 25, 2004 | 1646 |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| MPP | AA | 15 | Watanabe <i>et al.</i> , "Interleukin-4 as a Potent Inhibitor of Bone Resorption", <i>Biochemical and Biophysical Research Communications</i> , 172(3):1035-1041 (1990) | |
| ↑ | AB | 15 | Westermann <i>et al.</i> , "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides" <i>Biomedica Biochimica Acta</i> , 48(1):85-93 (1989) | |
| | AC | 15 | Wiktor-Jedrzejczak <i>et al.</i> , "Hematological Characterization of Congenital Osteopetrosis in <i>op/op</i> Mouse (Possible Mechanism for Abnormal Macrophage Differentiation)", <i>Journal of Experimental Medicine</i> , 156(5):1516-1527 (1982) | |
| | AD | 15 | Wiktor-Jedrzejczak <i>et al.</i> , "Total absence of colony-stimulating factor I in the macrophage-deficient osteopetrotic (<i>op/op</i>) mouse", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(12):4828-4832 (1990) | |
| | AE | 15 | Wiley <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis", <i>Immunity</i> , 3(6):673-682 (1995) | |
| | AF | 15 | Wong <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells", <i>Journal of Biological Chemistry</i> , 272(40):25190-25194 (1997) | |
| | AG | 15 | Wu-Pong, S., "Oligonucleotides: Opportunities for Drug Therapy and Research", <i>Pharmaceutical Technology</i> , 118:102-114 (1994) | |
| | AH | 15 | Yamaguchi <i>et al.</i> , "Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor", <i>Journal of Biological Chemistry</i> , 273(9):5117-5123 (1998) | |
| | AI | 15 | Yan and Chao, "Disruption of Cysteine-rich Repeats of the p75 Nerve Growth Factor Receptor Leads to Loss of Ligand Binding", <i>Journal of Biological Chemistry</i> , 266(18):12099-12104 (1991) | |
| | AJ | 15 | Yang <i>et al.</i> , "Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy", <i>Cancer Research</i> , 59(6):1236-1243 (1999) | |
| | | AK | 15 | Yasuda <i>et al.</i> , "Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL", <i>Proceedings of the National Academy of Sciences of USA</i> , 95(7):3597-3602 (1998) |
| ↓ | AL | 15 | Yoneda <i>et al.</i> , "Sumarin Suppresses Hypercalcemia and Osteoclastic Bone Resorption in Nude Mice Bearing a Human Squamous Cancer", <i>Cancer Research</i> , 55:1989-1993 (1995) | |
| MDP | AM | 15 | Yoshida <i>et al.</i> , "The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene", <i>Nature</i> , 345(6274):442-444 (1990) | |
| EXAMINER | | | DATE CONSIDERED | |
| MICHAEL POK | | | 3-16-06 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | | | | |